532 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
Sanofi (SNY) Olivier Brandicourt on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3993329-sanofi-sny-olivier-brandicourt-q2-2016-results-earnings-call-transcript?source=feed_sector_healthcare Jul 29, 2016 - Sanofi (NYSE:SNY)Q2 2016 Earnings CallJuly 29, 2016 8:30 am ETExecutivesGeorge Grofik - Vice President Investor Relations, SanofiOlivier Brandicourt - Chief Executive Officer & DirectorElias E. Zerhou
CNBC: Medivation sets mid-August deadline; SNY, PFE, GILD, CELG in play http://seekingalpha.com/news/3197917-cnbc-medivation-sets-mid-august-deadline-sny-pfe-gild-celg-play?source=feed_news_all Jul 29, 2016 - Medivation (MDVN +1.3%) has asked for indications of interest by mid-August, CNBC's David Faber says, with a number of pursuers in the mix. Earlier this mo
Bristol-Myers (BMY): Stock to Beat Earnings Again in Q2 http://www.zacks.com/stock/news/224851/bristol-myers-bmy-stock-to-beat-earnings-again-in-q2?cid=CS-ZC-FT-224851 Jul 25, 2016 - Bristol-Myers Squibb (BMY), which is set to report second-quarter 2016 results on Jul 28, reported a positive earnings surprise of 12.12% last quarter.
Celgene (CELG) Q2 Earnings: Can the Stock Pull a Surprise? http://www.zacks.com/stock/news/224843/celgene-celg-q2-earnings-can-the-stock-pull-a-surprise?cid=CS-ZC-FT-224843 Jul 25, 2016 - Celgene Corporation (CELG), which is set to report second-quarter 2016 results on Jul 28, reported a positive earnings surprise of 12.38% last quarter.
Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen http://www.zacks.com/stock/news/224756/zacks-industry-outlook-highlights-bristol-myers-pfizer-sanofi-amgen-and-biogen?cid=CS-ZC-FT-224756 Jul 25, 2016 - Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
Pharma Industry Outlook: Fundamentals Remain Strong http://www.zacks.com/commentary/86599/pharma-industry-outlook-fundamentals-remain-strong?cid=CS-ZC--86599 Jul 22, 2016 - Pharma Industry Outlook: Fundamentals Remain Strong
Actelion (ALIOF) Beats Q2 Earnings & Revenues, View Up http://www.zacks.com/stock/news/224669/actelion-aliof-beats-q2-earnings-revenues-view-up?cid=CS-ZC-FT-224669 Jul 22, 2016 - Actelion (ALIOF) reported second-quarter 2016 earnings of $2.13 per American Depository Receipt, up from the year-ago figure of $1.60.
Pfizer Publishes Final Data from Atopic Dermatitis Studies http://www.zacks.com/stock/news/223503/pfizer-publishes-final-data-from-atopic-dermatitis-studies?cid=CS-ZC-FT-223503 Jul 14, 2016 - Pfizer (PFE) announced findings from two pivotal phase III studies on crisaborole for the treatment of patients with mild-to-moderate atopic dermatitis.
Amgen's Repatha Gains FDA Approval for New Dosing Option http://www.zacks.com/stock/news/223161/amgens-repatha-gains-fda-approval-for-new-dosing-option?cid=CS-ZC-FT-223161 Jul 12, 2016 - Amgen's (AMGN) PCSK9 inhibitor Repatha becomes the first and the only one to gain FDA approval for a monthly single-dose administration.
Sanofi's (SNY) CEO Olivier Brandicourt on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3969909-sanofis-sny-ceo-olivier-brandicourt-q1-2016-results-earnings-call-transcript?source=feed_all_articles May 01, 2016 - Sanofi SA (NYSE:SNY) Q1 2016 Earnings Conference Call April 29, 2016 08:30 AM ET Executives Sebastien Martel - VP, IR Olivier Brandicourt - CEO Jerome Contamine - EVP & CFO Pascale Witz - EVP, Dia

Pages: 1...4748495051525354

<<<Page 52>